[Clinical trials and evaluation of Chinese patent medicine for chronic obstructive pulmonary disease].

• DOI: 10.19540/j.cnki.cjcmm.20210910.501
• Publication Date: 2022-05-01
• Authors: Chao-Nan Feng; Hai-Yin Hu; Zhaochen Ji; Xiaoyu Qiang; Zhe Chen; Yi Ou; Lujia Cao; Junhua Zhang
• Keywords: Blinding; Chinese patent medicine; Guideline

The clinical randomized controlled trials(RCTs) of Chinese patent medicine in the treatment chronic obstructive pulmonary disease(COPD) were reviewed and analyzed to provide references for research, guideline development, policy formulation, quality improvement evidence. On basis collection Traditional Medicine(TCM) Clinical Evidence Database System(EVDS), CNKI, Wanfang, SinoMed, Cochrane Library, PubMed, EMbase searched RCTs COPD as a source evidence from database inception December 31, 2019. publication time, sample size, intervention control measures, course treatment, outcome indicators, methodological trials evaluated. A total 733 included, among which 228 had size higher than 100, accounting 31.1% RCTs. Eighty-eight medicines involved, including 40 oral 48 injections. 327 mentioned measures(Chinese + conventional vs treatment), 43.0%. In addition, 94.40% reported 53.20% determined 8-14 d course. evaluation indicators adopted numerous, physicochemical indicators(70.57%) symptoms/signs(24.35%) most frequently employed. operation allocation concealment blinding was not standard. Registration procedure related ethics mostly missing. results indicate that there are prominent problems COPD, affecting reliability practicability trials. It is necessary further standardize design, implementation, highlight value improve